Dr. Tomasz M. Beer on Genomic Testing Resulting in New Single-Agent Treatments

February 3, 2016
Tomasz M. Beer, MD, FACP

​Tomasz M. Beer, MD, FACP, deputy director, Knight Cancer Institute, Oregon Health and Science University, discusses the potential for genomic tests to result in new treatments.

Tomasz M. Beer, MD, FACP, deputy director, Knight Cancer Institute, Oregon Health and Science University, discusses the potential for genomic tests to result in new treatments. Beer says if a target such as a DNA repair mutation is identified in a patient, then treatments targeting that defect can be prescribed.